Mon, Mar 2, 2015, 8:40 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Alimera Sciences, Inc. (ALIM) Message Board

  • galaberge galaberge Apr 19, 2013 3:39 PM Flag

    Most recent news....posted by the CEO of PSDV Dr. Ashton our partner in this lucrative business..

    I quote him ;

    "Our most recent product ILUVIEN® (developed with our partner Alimera Sciences) may fill some of those gaps– it provides 3 years of therapy for chronic Diabetic Macular Edema from a single injection and has been approved in multiple EU countries with first sales expected in Germany later this quarter. People following Alimera carefully may have seen that a price in Germany of €7,975 has been published. This is obviously great news. Now, the published price is essentially the “list price” and the ultimate sales price will likely be subject to various discounts to the list price. So this is consistent with Alimera’s statement that the Germany price will be comparable with the UK price of £5,500 (accepted by UK private insurers). In another positive development, Alimera recently stated that they had “submitted a response to the FDA’s CRL.” This is regulation speak for re-filing the NDA for ILUVIEN. The next development will hopefully be the acceptance of the re-filing for review and the issuance of a PDUFA date. This won’t mean that the FDA has accepted the product, only that it will review the application within a certain time period (the PFUFA date)."

    So we wait and load the boat of shares.

    Sentiment: Strong Buy

5.20-0.03(-0.57%)Mar 2 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SBA Communications Corp.
NASDAQMon, Mar 2, 2015 4:00 PM EST
NXP Semiconductors NV
NASDAQMon, Mar 2, 2015 4:00 PM EST